U.S. pharmaceutical giant Johnson & Johnson reports revenue in line with expectations for the third quarter. Adjusted earnings per share were better than expected.
Revenue rose 5.9% to USD 25.40 billion (23.99). This compares with FactSet analyst consensus of 25.38.
Adjusted earnings per share were USD 2.59 (2.80), which is 2.8% above analyst consensus of 2.52.
Johnson & Johnson, USD billionQ3-2026ConsensusChange versus consensusQ3-2025ChangeNet sales25.4025.380.1%23.995.9%Adjusted earnings per share, USD2.592.522.8%2.80-7.5%Consensus data from FactSet
